![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif)
Pharmacoeconomic Considerations in Pharmaceutical Company Promotions-Reply
Richard Levy, PhD
Arch Fam Med. 1994;3(12):1035.
References Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
1. Levy RA. Pharmaceutical Research: Therapeutic and Economic Value of Incremental Improvements. Reston, Va: National Pharmaceutical Council; 1990.
2. Yasuda SA, Woosley RL. The clinical value of FDA class C drugs approved from 1981 to 1988. Clin Pharmacol Ther. 1992;52:577-582.
PUBMED
|